The verdict
Our read at a glance.
Whether thymulin, nonathymulin, or serum thymic factor evidence supports any current, product-specific clinical claim beyond identity, zinc-dependent thymic hormone biology, and exploratory biomarker contexts.
- The signal
- The strongest evidence supports thymulin/nonathymulin as a defined zinc-dependent thymic nonapeptide and biomarker-linked signal. Human evidence is mostly older biomarker, endocrine-immunology, tissue, ex vivo immune-cell, and small historical clinical-context literature across zinc status, nutrition, aging, Crohn's disease, HIV/AIDS, renal disease, Down syndrome, diabetes, myasthenia gravis, neonatal physiology, rheumatoid arthritis, and multiple sclerosis. Preclinical studies map additional claims but do not establish human outcomes.
- The unknown
- Whether any historical signal translates to modern patient-centered outcomes, how older serum thymic factor nomenclature maps onto thymulin/nonathymulin across papers, and whether products discussed today match endogenous biology or older synthetic nonathymulin materials.
- Our read
- Source-rich, but low certainty for clinical claims. Thymulin belongs in a context-dependent safety watch because the source base is real, yet mostly older, biomarker-heavy, mechanistic, and identity-focused. Biomarker movement is not clinical outcome proof, and zinc-supplementation studies are not thymulin treatment studies.
The mechanism
How it works.
Thymulin is a thymic nonapeptide (a nine-amino-acid hormone) that is only biologically active once it binds a zinc atom. In its zinc-bound form it acts on T-cells, influencing their differentiation and the balance of cytokines they produce. Its activity in the blood tends to fall when zinc is low or the thymus ages. This zinc-dependent immune-hormone biology is reasonably well characterized, but it comes from older biomarker and lab studies and does not establish that giving thymulin improves outcomes in people.
Safety & regulatory boundary
The consequential part.
Official nomenclature sources identify nonathymulin as thymulin or serum thymic factor, but U.S. public records reviewed here did not identify an approved FDA thymulin/nonathymulin drug. DailyMed lists a nonathymulin homeopathic SPL with unapproved homeopathic marketing status; that listing is not FDA approval and is not evidence of safety or effectiveness. Product identity matters: endogenous thymulin biology, older synthetic FTS/nonathymulin studies, homeopathic labels, compounded preparations, research-use peptides, and internet-market products should not be treated as equivalent. Thymulin is also not Thymalin, thymosin alpha-1, thymalfasin, Zadaxin, TB-500, thymosin beta-4, thymosin beta-10, or a thymus extract.
What's next
What we're watching.
Modern controlled human outcomes, better product-identity documentation, regulator status records, safety reporting, and reviews that separate thymulin/nonathymulin from zinc-only studies, thymic extracts, Thymalin, thymosin alpha-1, and internet-market claims.
Context
Why this is discussed.
Thymulin appears in thymic-peptide discussions because older papers link it to zinc status, thymic endocrine activity, immune-cell function, aging biology, and small historical nonathymulin studies. Those discussions are often blurred with Thymalin, thymosin alpha-1, thymus extracts, or market products that are not interchangeable.
The evidence base
74 cited references.
Regulatory & labels3
FDA Global Substance Registration System · Current page checked 2026-05-16
World Health Organization International Nonproprietary Names · 1987
National Library of Medicine / DailyMed · Updated 2019-02-28; checked 2026-05-16
Peer-reviewed journals5
Bach JF, Dardenne M, Pleau JM, Rosa J · 1977
ScienceDirect indexed record · 1984
Journal of Biological Chemistry indexed record · 1986
Amor B, Dougados M, Mery C, Dardenne M, Bach JF · 1987
Goya RG, Brown OA, Pleau JM, Dardenne M · 2004
Indexed literature (PubMed)62
Pleau JM, Dardenne M, Blouquit Y, Bach JF · 1977
Dardenne M et al. · 1982
Journal of Biological Chemistry indexed record · 1988
Prasad AS et al. · 1988
Chandra RK · 1979
Wade S et al. · 1988
Jambon B et al. · 1988
Parent G et al. · 1994
Wade S et al. · 1985
Bensman A et al. · 1984
Travaglini P et al. · 1989
Togni E et al. · 1990
Brignola C et al. · 1993
Mocchegiani E et al. · 1990
Incefy GS et al. · 1986
Rubinstein A et al. · 1986
Consolini R et al. · 2000
Mocchegiani E et al. · 1995
Mocchegiani E, Muzzioli M · 2000
Consolini R et al. · 2000
Costarelli L et al. · 2014
Prasad AS et al. · 1993
Licastro F et al. · 1996
Mocchegiani E et al. · 1996
Meazza C et al. · 2007
Fabris N et al. · 1987
Molinero P et al. · 2000
Noureddin BN et al. · 2006
Safieh-Garabedian B et al. · 1993
Palacios R et al. · 1981
Palacios R, Alarcon-Segovia D · 1981
Jambon B et al. · 1981
Travaglini P et al. · 1992
Fabris N et al. · 1984
Licastro F et al. · 1993
Mocchegiani E et al. · 1989
Mocchegiani E et al. · 1999
Mocchegiani E et al. · 2000
Licastro F et al. · 1997
Palmer AC et al. · 2020
Faure GC et al. · 1987
Amor B et al. · 1984
Roullet E et al. · 1989
Bordigoni P et al. · 1982
Dokhelar MC et al. · 1983
Bach JF, Dardenne M · 1989
Reggiani PC et al. · 2014
Reggiani PC et al. · 2009
Dardenne M et al. · 1985
Dardenne M et al. · 1993
Pleau JM et al. · 1980
Coto JA et al. · 1992
Saha AR et al. · 1995
Savino W, Lepletier A · 2023
da Silva AL et al. · 2014
da Silva AL et al. · 2020
DiSilvestro RA et al. · 2021
Henriques-Coelho T et al. · 2008
Nasseri B et al. · 2019
Novoselova EG et al. · 2021
Lunin SM et al. · 2023
Novoselova EG et al. · 2018
Sponsor & other sources4
National Library of Medicine MeSH · 2026
National Library of Medicine RxNorm · Current page checked 2026-05-16
PubChem / National Center for Biotechnology Information · Current page checked 2026-05-16
PubChem / National Center for Biotechnology Information · Modified 2026-02-07; checked 2026-05-16
Keep reading